Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antigens Involved in Adaptive Immunity

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

Affinity and Avidity

Affinity and Avidity

Cross-reactivity

Cross-reactivity

Immunoprecipitation

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative sedimentation equilibrium analysis of two IgG1 glycoforms: IgGCri and IgGWid.

European biophysics journal : EBJ·2023

Same author

Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation.

Frontiers in immunology·2022

Same author

Micro-Heterogeneity of Antibody Molecules.

Experientia supplementum (2012)·2021

Same author

Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

Experientia supplementum (2012)·2021

Same author

Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody.

Cell·2020

Same author

Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope.

Cell reports·2017

Search research articles

Related Experiment Video

Updated: May 27, 2026

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Published on: September 2, 2022

Aggregation, immune complexes and immunogenicity.

|November 30, 2011

Summary

This summary is machine-generated.

Protein therapeutics can trigger immune responses, reducing effectiveness and causing adverse events. Aggregation of these drugs is a primary concern, especially for chronic disease treatments requiring long-term use.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: May 27, 2026

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Published on: September 2, 2022

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Area of Science:

Biopharmaceutical development
Immunology
Protein therapeutics

Background:

Protein therapeutics are crucial for treating various diseases.
Immune responses to protein therapeutics can lead to loss of efficacy and adverse events.
Immunogenicity is a significant challenge in biopharmaceutical development, particularly for chronic conditions.

Discussion:

Aggregation of protein therapeutics is a major contributor to immunogenicity.
Understanding and mitigating aggregation is critical for safe and effective protein-based drugs.
The biopharmaceutical industry faces challenges in managing immunogenicity for long-term therapeutic use.

Key Insights:

Protein aggregation is a key driver of immunogenicity.
Effective management of protein aggregation is essential for therapeutic success.
Addressing immunogenicity is vital for regulatory approval and patient safety.

Outlook:

Further research into controlling protein aggregation is needed.
Developing strategies to minimize immunogenicity will enhance protein therapeutic applications.
Continued focus on protein aggregation will improve chronic disease management.